Last reviewed · How we verify

GW642444 Inhalation Powder — Competitive Intelligence Brief

GW642444 Inhalation Powder (GW642444 Inhalation Powder) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta-2 agonist (LABA). Area: Respiratory / Pulmonology.

phase 3 Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor (ADRB2) Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

GW642444 Inhalation Powder (GW642444 Inhalation Powder) — GlaxoSmithKline. GW642444 is a long-acting beta-2 adrenergic receptor agonist that relaxes airway smooth muscle to improve airflow in respiratory diseases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GW642444 Inhalation Powder TARGET GW642444 Inhalation Powder GlaxoSmithKline phase 3 Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor (ADRB2)
Glycopyrrolate + Formoterol Glycopyrrolate + Formoterol Chiesi Farmaceutici S.p.A. marketed Long-acting muscarinic antagonist (LAMA) + long-acting beta-2 agonist (LABA) combination M3 muscarinic receptor; beta-2 adrenergic receptor
Formoterol Aldo Formoterol Aldo Fundacio Privada Mon Clinic Barcelona marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor
formoterol Turbuhaler 9µg formoterol Turbuhaler 9µg AstraZeneca marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor
Formoterol Inhalation Solution Formoterol Inhalation Solution Chiesi Farmaceutici S.p.A. marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor
Salmeterol(SN408D) Salmeterol(SN408D) GlaxoSmithKline marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor (ADRB2)
Arformoterol (Brovana) Arformoterol (Brovana) Trinity Health Of New England marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta-2 agonist (LABA) class)

  1. GlaxoSmithKline · 8 drugs in this class
  2. AstraZeneca · 5 drugs in this class
  3. Novartis · 3 drugs in this class
  4. Sumitomo Pharma America, Inc. · 3 drugs in this class
  5. Chiesi Farmaceutici S.p.A. · 3 drugs in this class
  6. Organon and Co · 2 drugs in this class
  7. Fundacio Privada Mon Clinic Barcelona · 2 drugs in this class
  8. Henan University of Traditional Chinese Medicine · 1 drug in this class
  9. Genentech, Inc. · 1 drug in this class
  10. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GW642444 Inhalation Powder — Competitive Intelligence Brief. https://druglandscape.com/ci/gw642444-inhalation-powder. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: